- Meeting abstract
- Open Access
Area-level socioeconomic status and variation in medication use among Medicaid enrollees with incident systemic lupus erythematosus, 2000 to 2004
© Feldman et al.; licensee BioMed Central Ltd. 2012
- Published: 27 September 2012
- Systemic Lupus Erythematosus
- Mycophenolate Mofetil
Differences in access to medications may be related to socioeconomic disparities in outcomes among individuals with systemic lupus erythematosus (SLE). We investigated county-level socioeconomic status (SES) and corticosteroid, hydroxychloroquine and immunosuppressant use among individuals in the low-income US Medicaid population.
From the US Medicaid Analytic eXtract (MAX) data, containing all billing claims from 2000 to 2004, we identified adults, aged 18 to 65, with incident SLE (≥3 SLE ICD-9 codes (710.0), >30 days apart, with 24 months of prior enrollment without SLE claims). Sex, age, race/ethnicity, ZIP code, and geographic region were obtained. We determined health professional shortage areas, number of state-level rheumatologists, and county-level SES using a validated composite of US Census variables. Our outcome measures were use at any time of corticosteroids, hydroxychloroquine, or an immunosuppressant (azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine or tacrolimus). We used multivariable logistic regression to examine relationships between sociodemographic variables and medication prescriptions.
Medication prescriptions among Medicaid enrollees with incident SLE, 2000 to 2004 according to county-level SESa
Increasing county-level SES
In higher SES areas, corticosteroid use among patients with incident SLE appears to be less frequent, while immunosuppressant use may be more frequent. Further studies are necessary to determine whether medication differences contribute to disparities in outcomes.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.